全文获取类型
收费全文 | 3887篇 |
免费 | 257篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 88篇 |
妇产科学 | 161篇 |
基础医学 | 492篇 |
口腔科学 | 101篇 |
临床医学 | 281篇 |
内科学 | 843篇 |
皮肤病学 | 173篇 |
神经病学 | 193篇 |
特种医学 | 133篇 |
外科学 | 739篇 |
综合类 | 8篇 |
预防医学 | 79篇 |
眼科学 | 103篇 |
药学 | 285篇 |
中国医学 | 5篇 |
肿瘤学 | 469篇 |
出版年
2021年 | 49篇 |
2020年 | 57篇 |
2019年 | 69篇 |
2018年 | 93篇 |
2017年 | 89篇 |
2016年 | 114篇 |
2015年 | 90篇 |
2014年 | 117篇 |
2013年 | 130篇 |
2012年 | 142篇 |
2011年 | 188篇 |
2010年 | 92篇 |
2009年 | 81篇 |
2008年 | 151篇 |
2007年 | 173篇 |
2006年 | 159篇 |
2005年 | 154篇 |
2004年 | 157篇 |
2003年 | 153篇 |
2002年 | 167篇 |
2001年 | 158篇 |
2000年 | 172篇 |
1999年 | 144篇 |
1998年 | 62篇 |
1997年 | 30篇 |
1996年 | 44篇 |
1995年 | 24篇 |
1994年 | 31篇 |
1993年 | 32篇 |
1992年 | 102篇 |
1991年 | 93篇 |
1990年 | 93篇 |
1989年 | 122篇 |
1988年 | 86篇 |
1987年 | 80篇 |
1986年 | 59篇 |
1985年 | 59篇 |
1984年 | 40篇 |
1983年 | 31篇 |
1981年 | 13篇 |
1979年 | 20篇 |
1978年 | 27篇 |
1977年 | 20篇 |
1976年 | 14篇 |
1975年 | 15篇 |
1973年 | 15篇 |
1970年 | 20篇 |
1969年 | 13篇 |
1968年 | 14篇 |
1966年 | 14篇 |
排序方式: 共有4166条查询结果,搜索用时 22 毫秒
1.
2.
3.
4.
Eo Toriyama Tomoko Hata Kenichi Yokota Masahiko Chiwata Rena Kamijo Miki Hashimoto Masataka Taguchi Makiko Horai Masatoshi Matsuo Emi Matsuo Yumi Takasaki Yasuhisa Kawaguchi Hidehiro Itonaga Shinya Sato Koji Ando Yasushi Sawayama Jun Taguchi Yoshitaka Imaizumi Hideki Tsushima Tatsuro Jo Shinichiro Yoshida Yukiyoshi Moriuchi Yasushi Miyazaki 《Cancer science》2020,111(12):4490
The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients. 相似文献
5.
Dermoscopic features of hidroacanthoma simplex: Usefulness in distinguishing it from Bowen's disease and seborrheic keratosis 下载免费PDF全文
Chihiro Shiiya Hiroo Hata Yuka Inamura Keisuke Imafuku Shinya Kitamura Hiromi Fujita Hiroshi Shimizu 《The Journal of dermatology》2015,42(10):1002-1005
Hidroacanthoma simplex (HAS) is a rare benign eccrine adnexal tumor. HAS is sometimes clinically or pathologically misdiagnosed as squamous cell carcinoma in situ (Bowen's disease; BD), seborrheic keratosis (SK) or other adnexal tumor. To date, there has never been a report focusing on dermoscopic features to distinguish HAS from BD and SK. We found the following dermoscopic findings to be characteristic of HAS: fine black dots/globules (75% of cases) and fine scales arranged annularly (100% of cases). In contrast, glomerular vessels, which are typically observed in BD, were not seen in any of the four cases. Cerebriform appearance and milia‐like cysts, which are typically observed in SK, were also not seen in any of the four cases. The existence of “scattered fine black dots/globules” and “fine scales arranged annularly”, and the absence of the glomerular vessels, may contribute to precise diagnosis of HAS. Even though HAS resembles BD or SK clinically, it can be distinguished from these by the characteristic dermoscopic features. 相似文献
6.
Atsushi Hata Takahiro Nakajima Keisuke Matsusaka Masaki Fukuyo Junichi Morimoto Takayoshi Yamamoto Yuichi Sakairi Bahityar Rahmutulla Satoshi Ota Hironobu Wada Hidemi Suzuki Hisahiro Matsubara Ichiro Yoshino Atsushi Kaneda 《International journal of cancer. Journal international du cancer》2020,146(2):388-399
7.
8.
Yutaka Fujioka Nobuhiro Hata Ryusuke Hatae Satoshi O. Suzuki Yuhei Sangatsuda Yukiko Nakahara Masahiro Mizoguchi Koji Iihara 《Neuropathology》2020,40(1):99-103
Diffuse midline glioma, H3 K27M mutant arises from midline structures of the central nervous system and predominately affects pediatric patients. However, this disease entity was only recently established, and the clinical phenotypic spectrum remains largely unclear. We herein report a rare case of diffuse midline glioma, H3 K27M mutant with an unusual distribution in an elderly woman who presented with a diffuse glioma that invaded both sides of the thalami, and left hippocampus and frontoparietal lobes, thus mimicking a hemispheric malignant glioma. A biopsy of the lobular lesion led to a molecular diagnostic confirmation of diffuse midline glioma, H3 K27M mutant. The patient received concurrent bevacizumab and temozolomide therapy with radiation therapy and survived for 30 months. This case highlights the possibility that a glioma with cerebral hemispheric spread in an elderly patient may harbor the H3 K27M mutation. 相似文献
9.
Shoko Sadashima Satoshi O. Suzuki Hironori Haruyama Nobutaka Mukae Yutaka Fujioka Nobuhiro Hata Masahiro Mizoguchi Keisuke Ishimatsu Akio Hiwatashi Toru Iwaki 《Neuropathology》2020,40(6):646-650
Here, we report a juvenile (18-year-old male) case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF mutation and a focal atypical feature resembling diffuse astrocytoma. The patient presented with refractory temporal lobe epilepsy. Subsequently, magnetic resonance imaging revealed a hyperintense lesion in the right temporal lobe on fluid attenuated inversion recovery images. The patient underwent right lateral temporal lobectomy and amygdalohippocampectomy. Histopathologically, the tumor showed isomorphic, diffuse, infiltrative proliferation of glial tumor cells and intense CD34 immunoreactivity. The tumor cells were immunonegative for isocitrate dehydrogenase 1 (IDH1) R132H and BRAF V600E. Notably, the tumor cells showed the lack of nuclear staining for α-thalassemia/mental retardation syndrome, X-linked (ATRX). In addition, the Ki-67 labeling index, using a monoclonal antibody MIB-1, was elevated focally at tumor cells with p53 immunoreactivity. Molecular analyses identified a BRAFA598T mutation, the first case reported in a glioma. BRAFA598T is predicted to result in loss of kinase action; however, inactive mutants can stimulate mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling through CRAF activation. Thus, according to the recent update of the consortium to inform molecular and practical approaches to central nervous system tumor taxonomy (cIMPACT-NOW update 4), our case is also compatible with diffuse glioma with the mitogen-activated protein kinase (MAPK) pathway alteration. Thorough immunohistochemical and molecular studies are necessary for diagnosis of epilepsy-associated, diffuse gliomas. Partial resemblance in histopathological and molecular genetic features to diffuse astrocytoma also calls for attention. 相似文献
10.